Webinar replay

Biopharma Dealmaking in 2022: Trends & Forecasts

Download the Biopharma Dealmaking eBook now

2021 was a busy year in biopharma dealmaking. There were billion-dollar deals, a flood of funding, increased early-stage partnering, and new therapeutic areas and platforms coming online. Now, armed with record amounts of cash and funding, 2022 is poised to be another remarkable year for life science companies in general and partnering specifically.

Join Chris Dokomajilar, CEO at DealForma, and Echo Zhang, Product Strategy Director at Inova, as they discuss:

  • Partnering and dealmaking trends in 2021
  • What lies ahead in 2022
Watch this replay to get expert insights from our panelists:
Chris Dokomajilar
Chris Dokomajilar
Founder & CEO
DealForma
echo-zhang
Echo Zhang
Product Strategy Director
Inova

Please complete the form below

All fields marked with a * are required.

By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.
Biopharma Dealmaking in 2022-03
Biopharma Dealmaking in 2022-08
Biopharma Dealmaking in 2022-12
Preview eBook

Download the Biopharma Dealmaking in 2022 eBook:

  • 2021 Deal Numbers: Number of Deals Across Therapeutics and Platforms.
  • Asset Types and Progress: Large Cap Biopharma Dealmaking Heading into 2022.
  • Healthcare and Life Sciences Venture: Venture Totals into Healthcare and Life Sciences by Subsector.
Download the Biopharma Dealmaking eBook now

About Inova

Inova accelerates partnering for the future of medicine. Our cloud-based solutions help life science companies manage their biopharma opportunities more efficiently. They find all their partnering information in one place, track their deals and alliances easily and report on their pipeline and activities in seconds.
We have also developed strategic partnerships that make data from the 20 biggest biopharma events automatically available in Inova, providing our users with always up-to-date company and contact information. Over 150 life science companies, including 50% of the top 50 pharmaceutical companies and many midsize pharma and innovative biotechs already use Inova.